Navigation Links
PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
Date:3/27/2008

BOSTON, March 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation ("PAREXEL") (Nasdaq: PRXL) today announced that it has expanded its minority interest ownership in the clinical pharmacology business of Synchron Research in Ahmedabad, India. The Company also announced the sale of a bioanalytical laboratory in Poitiers, France to a subsidiary of Synchron, SYNEXEL Research International.

Under the terms of the new agreement, PAREXEL's ownership interest in the Ahmedabad Phase I business has increased from 19.5% to 31.0% on a fully diluted basis, at a cost of approximately $5.0 million dollars. In a separate transaction, PAREXEL sold the Poitiers business to Synchron's SYNEXEL Research International for approximately $6.7 million dollars. Staff of the bioanalytical lab in Poitiers, France will join Synchron's bioanalytical business unit.

"Over the past several years, PAREXEL has developed a strong global clinical pharmacology capability, through both organic growth and acquisitions. As a result, we are an industry leader in expertise-based Phase I studies," said Josef H. von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. "PAREXEL's increased investment in Synchron's clinical pharmacology business demonstrates our commitment to helping clients select the most promising compounds earlier by providing complex, multi-site Phase I and Proof of Concept studies. We have a long-term commitment to conducting high quality clinical studies in India, and continue to strengthen our presence, both in India and globally, to help clients bring important new biopharmaceutical products to market."

In 2004, PAREXEL entered into an exclusive strategic collaboration with Synchron, a privately-held contrac
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
2. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
3. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
4. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
5. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
6. PAREXEL International Announces 2-For-1 Stock Split
7. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
8. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
9. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
11. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Jan. 3 Escalon Medical Corp.,(Nasdaq Capital Market: ... 510(k) clearance from the U.S. Food and Drug,Administration ... The MASTER-VU(TM) System consists of a B-scan probe ... (via a USB cable,connection) using Sonomed,s proprietary software, ...
... Jan. 3 Cinpathogen, through its,partnership in the ... clinical diagnostic technology consulting,services to Shanghai area hospitals. ... the,Shanghai Health Study, the Center has diagnosed and ... in collaboration with area,hospitals and colleagues at Fudan ...
... KENILWORTH, N.J., Jan. 2 Schering-Plough,Corporation (NYSE: ... and Drug,Administration (FDA) has assigned priority review status ... Sugammadex is specifically designed to reverse the ... States as ZEMURON(R) (rocuronium,bromide) and vecuronium bromide. Muscle ...
Cached Biology Technology:Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 2Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... New York University biologists have uncovered how the innate ... neurons. The findings, published as the cover study in ... neurons fight the virus at multiple stages--by preventing the ... virus' release, which could infect other cells in the ...
... today in the journal Genome,Research that they have ... a 554-kilobase-pair genomic,segment near the centromere of the ... genes that could be implicated in,sex-associated height differences ... one of the few holes remaining in the,"finished" ...
... in comparison to the 3.2 gigabases of its human ... 14 proteins, which play different roles in promoting viral ... host’s cellular machinery—including RNA polymerases, which carry out transcription—to ... chromosomal DNA. Once the virus is integrated (now called ...
Cached Biology News:NYU Study Reveals How Brain's Immune System Fights Viral Encephalitis 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Novel Enzyme Shows Potential As An Anti-HIV Target 2Novel Enzyme Shows Potential As An Anti-HIV Target 3